Business Description
Mayne Pharma Group Ltd
ISIN : AU000000MYX0
Total Employee Number:
160Compare
Compare
Traded in other countries / regions
MYX.AustraliaMAYNF.USAHG6.Germany IPO Date
2007-06-29Description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.64 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 1.44 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | -0.88 | |||||
Beneish M-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.1 | |||||
3-Year EPS without NRI Growth Rate | 9.6 | |||||
3-Year FCF Growth Rate | 14.3 | |||||
3-Year Book Growth Rate | -10.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.73 | |||||
9-Day RSI | 82.35 | |||||
14-Day RSI | 72.97 | |||||
3-1 Month Momentum % | 5.73 | |||||
6-1 Month Momentum % | -22.83 | |||||
12-1 Month Momentum % | -52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.33 | |||||
Quick Ratio | 1.14 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 127.26 | |||||
Days Sales Outstanding | 166.62 | |||||
Days Payable | 336.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 2.7 | |||||
Shareholder Yield % | -1.21 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.31 | |||||
Operating Margin % | -23.54 | |||||
Net Margin % | -20.62 | |||||
EBITDA Margin % | 7.29 | |||||
FCF Margin % | -0.29 | |||||
OCF Margin % | 5.36 | |||||
ROE % | -21.36 | |||||
ROA % | -8.09 | |||||
ROIC % | -12.75 | |||||
3-Year ROIIC % | -7.04 | |||||
ROC (Joel Greenblatt) % | -44.72 | |||||
ROCE % | -5.46 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 22.68 | |||||
PS Ratio | 0.54 | |||||
PB Ratio | 0.64 | |||||
Price-to-Operating-Cash-Flow | 9.72 | |||||
EV-to-EBIT | -4.85 | |||||
EV-to-Forward-EBIT | 463.45 | |||||
EV-to-EBITDA | 6.78 | |||||
EV-to-Forward-EBITDA | 4.42 | |||||
EV-to-Revenue | 0.49 | |||||
EV-to-Forward-Revenue | 0.59 | |||||
EV-to-FCF | -156.25 | |||||
Price-to-GF-Value | 0.53 | |||||
Price-to-Median-PS-Value | 0.37 | |||||
Earnings Yield (Greenblatt) % | -20.65 | |||||
FCF Yield % | -0.52 | |||||
Forward Rate of Return (Yacktman) % | -89.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mayne Pharma Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 403.627 | ||
| EPS (TTM) (A$) | -1.06 | ||
| Beta | 0.3914 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.06 | ||
| Volatility % | 46.65 | ||
| 14-Day RSI | 72.97 | ||
| 14-Day ATR (A$) | 0.117241 | ||
| 20-Day SMA (A$) | 2.396 | ||
| 12-1 Month Momentum % | -52 | ||
| 52-Week Range (A$) | 2.04 - 6.5 | ||
| Shares Outstanding (Mil) | 81.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mayne Pharma Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mayne Pharma Group Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-10-13 | In 104 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-28 09:30 | In 59 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 58 days | ||
| Second quarter earnings conference call for 2026 | 2026-02-23 09:30 | 2.65 (-1.49%) | ||
| Second quarter earnings results for 2026 | 2026-02-23 | 2.65 (-1.49%) | ||
| General meeting for 2025 | 2026-01-29 10:00 | 2.80 (-1.06%) | ||
| Annual report for 2025 | 2025-10-13 | 5.85 (+1.39%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-29 09:30 | 5.03 (-2.33%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 5.03 (-2.33%) | ||
| Second quarter earnings conference call for 2025 | 2025-02-26 09:30 | 7.22 (+0.28%) |
Show
Entries
Mayne Pharma Group Ltd Frequently Asked Questions
What is Mayne Pharma Group Ltd(ASX:MYX)'s stock price today?
The current price of ASX:MYX is A$2.79. The 52 week high of ASX:MYX is A$6.50 and 52 week low is A$2.04.
When is next earnings date of Mayne Pharma Group Ltd(ASX:MYX)?
The next earnings date of Mayne Pharma Group Ltd(ASX:MYX) is 2026-08-28 Est..
Does Mayne Pharma Group Ltd(ASX:MYX) pay dividends? If so, how much?
Mayne Pharma Group Ltd(ASX:MYX) does not pay dividend.
Press Release
Articles on Mayne Pharma Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers